Skip to main content

Idecabtagene Vicleucel

(I-deh-KAB-tuh-jeen vik-LOO-sel)

This page contains brief information about idecabtagene vicleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Abecma
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Idecabtagene vicleucel is approved to treat:

Idecabtagene vicleucel is only available as part of a special program called Abecma REMS (Risk Evaluation and Mitigation Strategies).

More About Idecabtagene Vicleucel

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

Targeted Cancer Therapies

T-cell Transfer Therapy

CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

Clinical Trials Accepting Patients

Find Clinical Trials for Idecabtagene Vicleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: